RICHMOND, Va.--(BUSINESS WIRE)--Insmed Inc. (Nasdaq:INSM), a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs, today announced the completion of development of two key follow on biologics at its facilities in Boulder, Colorado. The development of INS-19 (Granulocyte Colony Stimulating Factor or G-CSF) and INS-20 (Peg G-CSF) represents a significant milestone for Insmed. By achieving these critical development milestones, Insmed is positioned to initiate clinical studies in the first half of 2008.
